167 related articles for article (PubMed ID: 15806488)
1. Cyclophosphamide or chlorambucil therapy is indicated in idiopathic membranous nephropathy with strong risk factors for progression.
Hebert LA; Rovin BH; Agarwal AK; Spetie DN
Am J Kidney Dis; 2005 Apr; 45(4):788-9; author replyy 789-90. PubMed ID: 15806488
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis.
Ren S; Wang Y; Xian L; Toyama T; Jardine M; Li G; Perkovic V; Hong D
PLoS One; 2017; 12(9):e0184398. PubMed ID: 28898290
[TBL] [Abstract][Full Text] [Related]
3. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
Ponticelli C; Altieri P; Scolari F; Passerini P; Roccatello D; Cesana B; Melis P; Valzorio B; Sasdelli M; Pasquali S; Pozzi C; Piccoli G; Lupo A; Segagni S; Antonucci F; Dugo M; Minari M; Scalia A; Pedrini L; Pisano G; Grassi C; Farina M; Bellazzi R
J Am Soc Nephrol; 1998 Mar; 9(3):444-50. PubMed ID: 9513907
[TBL] [Abstract][Full Text] [Related]
4. Oral cyclophosphamide versus chlorambucil in the treatment of patients with membranous nephropathy and renal insufficiency.
Branten AJ; Reichert LJ; Koene RA; Wetzels JF
QJM; 1998 May; 91(5):359-66. PubMed ID: 9709470
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic membranous nephropathy: outline and rationale of a treatment strategy.
du Buf-Vereijken PW; Branten AJ; Wetzels JF
Am J Kidney Dis; 2005 Dec; 46(6):1012-29. PubMed ID: 16310567
[TBL] [Abstract][Full Text] [Related]
6. Preserving renal function in patients with membranous nephropathy: daily oral chlorambucil compared with intermittent monthly pulses of cyclophosphamide.
Reichert LJ; Huysmans FT; Assmann K; Koene RA; Wetzels JF
Ann Intern Med; 1994 Sep; 121(5):328-33. PubMed ID: 8042821
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of immunosuppressive treatment in patients with membranous nephropathy and renal insufficiency.
Wetzels JF; Reichert LJ
Kidney Int Suppl; 1997 Oct; 61():S63-6. PubMed ID: 9328969
[No Abstract] [Full Text] [Related]
8. Treatment of membranous nephropathy.
Ponticelli C; Passerini P
Nephrol Dial Transplant; 2001; 16 Suppl 5():8-10. PubMed ID: 11509678
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids, cyclophosphamide, and chlorambucil therapy of membranous nephropathy.
Passerini P; Ponticelli C
Semin Nephrol; 2003 Jul; 23(4):355-61. PubMed ID: 12923723
[TBL] [Abstract][Full Text] [Related]
10. Therapy of membranous nephropathy with severe azotemia.
Prabhakar S; Kahn T
Clin Nephrol; 1996 Jun; 45(6):419. PubMed ID: 8793240
[No Abstract] [Full Text] [Related]
11. [Treatment of membranous nephropathy with chronic renal insufficiency].
Passerini P; Leoni A
G Ital Nefrol; 2008; 25 Suppl 44():76-82. PubMed ID: 19048590
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy with cyclophosphamide and prednisolone in severe idiopathic membranous nephropathy.
Kibriya MG; Tishkov I; Nikolov D
Nephrol Dial Transplant; 1994; 9(2):138-43. PubMed ID: 8190328
[TBL] [Abstract][Full Text] [Related]
13. Restrictive use of immunosuppressive treatment in patients with idiopathic membranous nephropathy: high renal survival in a large patient cohort.
du Buf-Vereijken PW; Feith GW; Hollander D; Gerlag PG; Wirtz JJ; Noordzij TC; Wetzels JF;
QJM; 2004 Jun; 97(6):353-60. PubMed ID: 15152109
[TBL] [Abstract][Full Text] [Related]
14. Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial.
Hofstra JM; Branten AJ; Wirtz JJ; Noordzij TC; du Buf-Vereijken PW; Wetzels JF
Nephrol Dial Transplant; 2010 Jan; 25(1):129-36. PubMed ID: 19666912
[TBL] [Abstract][Full Text] [Related]
15. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands.
Hofstra JM; Wetzels JF
Nephrol Dial Transplant; 2008 Nov; 23(11):3534-8. PubMed ID: 18559961
[TBL] [Abstract][Full Text] [Related]
16. [Membranous nephropathy].
Passos EM; Legallicier B; Godin M
Rev Prat; 2003 Nov; 53(18):2033-8. PubMed ID: 15008218
[TBL] [Abstract][Full Text] [Related]
17. ACTH and azathioprine: antiproteinuric and lipid-lowering effect in the course of idiopathic membranous glomerulonephritis.
Gigante A; Rosato E; Liberatori M; Gasperini ML; Giannakakis K; Barbano B; Cianci R; Salsano F; Amoroso A
J Biol Regul Homeost Agents; 2012; 26(1):135-8. PubMed ID: 22475105
[TBL] [Abstract][Full Text] [Related]
18. A 10-year follow-up of idiopathic membranous nephropathy patients on steroids and cyclophosphamide: a case series.
Ram R; Guditi S; Kaligotla Venkata D
Ren Fail; 2015 Apr; 37(3):452-5. PubMed ID: 25594615
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial.
Howman A; Chapman TL; Langdon MM; Ferguson C; Adu D; Feehally J; Gaskin GJ; Jayne DR; O'Donoghue D; Boulton-Jones M; Mathieson PW
Lancet; 2013 Mar; 381(9868):744-51. PubMed ID: 23312808
[TBL] [Abstract][Full Text] [Related]
20. Application of artificial neural networks in estimating predictive factors and therapeutic efficacy in idiopathic membranous nephropathy.
Naumovic R; Furuncic D; Jovanovic D; Stosovic M; Basta-Jovanovic G; Lezaic V
Biomed Pharmacother; 2010 Nov; 64(9):633-8. PubMed ID: 20888177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
